GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley Sells 263 Shares

GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley sold 263 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $78.39, for a total transaction of $20,616.57. Following the transaction, the chief financial officer now directly owns 23,406 shares in the company, valued at $1,834,796.34. The trade was a 1.11 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Kevin Feeley also recently made the following trade(s):

• On Thursday, November 21st, Kevin Feeley sold 12,019 shares of GeneDx stock. The shares were sold at an average price of $73.76, for a total transaction of $886,521.44.
• On Tuesday, October 29th, Kevin Feeley sold 274 shares of GeneDx stock. The stock was sold at an average price of $66.60, for a total value of $18,248.40.
• On Monday, September 9th, Kevin Feeley sold 895 shares of GeneDx stock. The shares were sold at an average price of $33.33, for a total value of $29,830.35.

GeneDx Stock Performance

Shares of NASDAQ WGS opened at $75.05 on Wednesday. The business’s 50-day simple moving average is $64.42 and its 200-day simple moving average is $42.26. GeneDx Holdings Corp. has a 52 week low of $1.45 and a 52 week high of $89.11. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.27 and a current ratio of 2.40. The firm has a market cap of $2.06 billion, a price-to-earnings ratio of -24.13 and a beta of 2.03.

GeneDx (NASDAQ:WGS) last announced its quarterly earnings results on Tuesday, October 29th. The company reported $0.04 EPS for the quarter, beating the consensus estimate of ($0.21) by $0.25. GeneDx had a negative return on equity of 13.35% and a negative net margin of 31.25%. The company had revenue of $76.90 million for the quarter, compared to the consensus estimate of $64.98 million. During the same quarter last year, the company posted ($0.82) earnings per share. The company’s revenue for the quarter was up 44.3% compared to the same quarter last year. As a group, equities research analysts expect that GeneDx Holdings Corp. will post -0.24 earnings per share for the current fiscal year.

Hedge Funds Weigh In On GeneDx

A number of institutional investors have recently made changes to their positions in WGS. Renaissance Technologies LLC bought a new position in GeneDx during the second quarter worth $2,362,000. Chartwell Investment Partners LLC acquired a new stake in GeneDx in the 3rd quarter worth $1,722,000. Lisanti Capital Growth LLC bought a new position in shares of GeneDx during the 3rd quarter worth about $1,554,000. Millennium Management LLC raised its position in shares of GeneDx by 193.5% during the second quarter. Millennium Management LLC now owns 311,401 shares of the company’s stock valued at $8,140,000 after buying an additional 205,318 shares during the last quarter. Finally, Algert Global LLC bought a new stake in shares of GeneDx in the second quarter valued at about $356,000. 61.72% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the company. The Goldman Sachs Group lifted their price target on GeneDx from $54.00 to $70.00 and gave the company a “neutral” rating in a report on Wednesday, October 30th. Craig Hallum lifted their target price on shares of GeneDx from $70.00 to $95.00 and gave the company a “buy” rating in a research note on Wednesday, October 30th. Finally, Wells Fargo & Company boosted their target price on shares of GeneDx from $34.00 to $75.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 30th. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, GeneDx presently has an average rating of “Moderate Buy” and an average target price of $59.33.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.